SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Kemia, Inc. Announces Completion Of Phase I Trials For Oral Anti-Inflammatory Drug; KC706, A p38 MAP Kinase Inhibitor, Targets Inflammatory Conditions Including Arthritis, Psoriasis, And Cardiovascular Disease